Missing steps in the STAIR case: A Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 28, Issue 1, 2008, Pages 217-219

  Feuerstein, Giora Z ^a   Zaleska, Margaret M ^a   Krams, Michael ^a   Wang, Xinkang ^a   Day, Mark ^a   Rutkowski, Julia L ^a   Finklestein, Seth P ^b   Pangalos, Menelas N ^a   Poole, Michael ^a   Stiles, Gary L ^a   Ruffolo, Robert R ^a   Walsh, Frank L ^a  

^a PFIZER INC   (United States)

^b Biotrofix Inc   (United States)

Author keywords

Focal ischemia; Free radicals; Ischemia; Neuroprotection; NXY 059; Stroke; Translational Medicine

Indexed keywords

DISUFENTON SODIUM;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; GOVERNMENT; HUMAN; NOTE; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME;

BENZENESULFONATES; BRAIN ISCHEMIA; CARDIOVASCULAR AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; ENDPOINT DETERMINATION; GUIDELINES AS TOPIC; HUMANS; MODELS, CARDIOVASCULAR; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT SELECTION; STROKE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 37549068172     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600516     Document Type: Note

References (8)

1. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Cesare Fieschi C, Kaste M, Orgogozo J-M, Chamorro A, Desmet A (2002) For the European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (Trafermin) in Acute Stroke: results of the European-Australian Phase II/III Safety and Efficacy Trial. Cerebrovasc Dis 14:239-51
2. Green AR, Ashwood T (2005) Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Current Drug Targets - CNS Neurol Disord 4:109-85
3. Hess DC (2006) NXY-059: a hopeful sign in the treatment of stroke. Stroke 37:2649-50
4. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Dienr HC, Grotta J, Lyden P, Shuaib A, Hardenmaek HG, Wasiewski HG (2006) For the Stroke-Acute Ischemic NXY Treatment (SAINT I) investigators. NXY-059 for acute ischemic stroke. New Engl J Med 354:588-600
5. Marshal WBJ, Duffin KJ, Green AR, Ridely RM (2001) NXY-059, a free radical trapping agent, substantially lessens the functional disability resulting from cerebra ischemia in the primate species. Stroke 32:190-7
6. Pearson H (2006) SAINT II. The bitterest pill. Nature 444:532-3
7. Stroke Therapy Academic Industry Round table (STAIR) (2005) Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Round table (STAIR)-IV. Stroke 36:1808-13
8. Stroke Therapy Academic Industry Round table (STAIR) (Fisher M, Chair) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-82